InvestorsHub Logo
Followers 51
Posts 6706
Boards Moderated 0
Alias Born 01/17/2011

Re: None

Thursday, 08/15/2013 4:11:58 PM

Thursday, August 15, 2013 4:11:58 PM

Post# of 75926
My conclusion thus far.

The CE mark is a significant milestone. Those on both sides of the argument seem to clearly believe this. With all of the arguments against SNDY, it is clear all believe this to be a big achievement for the company and a lot of money and dilution has gone into ensuring this would happen. So all sides including the company believe this is a big achievement.

Will this CE mark generate significant revenue? Not by itself but it opens markets. Who will be selling this product and who will be buying these products? Who knows at this point. I haven't seen a real answer but it would be a prerequisite to sell the company or merge.

I also don't see anyone arguing that mammoview does not work. So that would be the biggest and best argument to me but it is pretty obvious to me and from reading some of the technical docs, that it probably does work. How come it hasn't been picked up more my others, journals, every hospital in the free world wanting it? Does make you wonder.

I don't see any real short volume and I am not sure you even could short this stock. The downside and upside and the fees probably make this a poor choice.

Is the argument really about a trading opportunity and entry price? Probably, at least it would seem that way.

Buyout? For the tech maybe but the trading wouldn't indicate it so far from what I can see but maybe with CE mark as some are predicting.

Will I buy some more shares? Probably